Effect of orlistat on serum uric acid level in adults: A systematic review and meta‐analysis of randomised controlled trials. Issue 11 (24th August 2021)

• Record Type: Journal Article
• Authors: Noori, Soheila; Mirzababaei, Atieh; Amini, Mohammad Reza; Clark, Cain C. T.; Mirzaei, Khadijeh
• Is Part Of: International journal of clinical practice. Volume 75:Issue 11(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-24
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.14674
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Objective: Hyperuricemia increases the risk of gout and cardiovascular diseases. Obesity increases the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat on serum uric acid (SUA) are still controversial. The aim of this meta‐analysis was to evaluate the influence of orlistat on SUA levels in adults. Methods: Relevant studies, published up to May 2020, were searched systematically through PubMed/Medline, Scopus and Google Scholar. All relevant randomised controlled clinical trials were included. Meta‐analysis was performed using random‐effect model. Subgroup analysis, sensitivity analysis and meta‐regression were also carried out. Results: Overall 7 trials (9 datasets) that enrolled 1786 subjects were included. Orlistat showed in a significant change in SUA level (Difference in means: −17.661 μmol, 95% CI: −31.615 to −3.707, P = .01). A low heterogeneity observed across the studies ( I 2 = 25.119%). After categorising studies on the basis of duration and sample size, the effect of orlistat on SUA was significant. The results of meta‐regression were showed that significant relationships were not found between orlistat and SUA in the duration of intervention. Conclusion: We found a significant reduction in SUA following orlistat therapy in adults.